+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Healthcare Licensing - Global Trends: By Region (Emerging Markets) Mid-Year Review

  • ID: 4604791
  • Report
  • July 2018
  • Region: Global
  • 53 pages
  • FinGlobe, Inc
1 of 2
This mid-year review report provides comprehensive analysis on all such licensing deals and negotiations that took place between healthcare companies of Emerging Markets during January 1, 2018 to June 30, 2018, categorized and summarized by various important aspects such as key countries, healthcare sub-sector, market capitalization groups, medicine groups, licensing payment arrangements, worldwide vs domestic licensing, and R&D vs commercialization licensing. Such detailed analysis helps to understand the licensing trends and directions during this time period in the healthcare segments of Emerging Markets.

Key Features:
  • 6 months’ healthcare licensing transactions of Emerging Markets analyzed at one place
  • Small, medium and big multinational/non-multinational companies covered
  • Curated categorizations of licensing details
  • 8+ variables reflecting different forms of transactions done
  • Licensing trends and directions summarized
The Report is useful to:
  • Healthcare companies of Emerging Markets planning to introduce products in other countries
  • Companies active in R&D and seeking new market base
  • Healthcare company executives of Emerging Markets negotiating licensing deals
  • Investors analyzing varied kinds of transaction options for licensing deals in Emerging Markets
Key analysis provided: January-June 2018
  • Total number of licensing deals signed by companies of Emerging Markets
  • Total number of companies/institutes of Emerging Markets involved in the licensing deals
  • Most licensing deals signed by companies of which sub-industry within healthcare sector
  • Most licensing deals signed by which country’s companies
  • Most licensing deals signed by which market capitalization group’s companies
  • Most licensing deals signed by which medicine groups
  • Licensing payment arrangements most followed in the licensing deals
  • Number of domestic and worldwide licensing
  • Number of R&D and commercialization licensing
Note: Product cover images may vary from those shown
2 of 2
Introduction

Research Design
Chapter 1: Analysis of healthcare inventions of Emerging Markets licensed during last six months
1.1 Countries with most licensing deals
1.2 Healthcare sub-sector with most licensing deals
1.3 Market capitalization groups with most licensing deals
1.4 Medicine groups most active in licensing deals
1.5 Licensing payment arrangements most followed
1.6 Worldwide licensing vs domestic licensing
1.7 R&D licensing vs commercialization licensing
Chapter 2: Analysis of licensing deals of Emerging Markets by healthcare sub-sector during last six months
2.1 Licensing deals for each of the healthcare sub-sector for each of the country
2.2 Licensing deals for each of the healthcare sub-sector across each of the regions
2.3 Licensing deals for each of the healthcare sub-sector for each of the marketcap group
2.4 Licensing deals for each of the healthcare sub-sector for each of the medicine group
Chapter 3: Analysis of licensing deals of Emerging Markets by marketcap groups during last six months
3.1 Licensing deals for each of the marketcap group for each of the country
3.2 Licensing deals for each of the marketcap group across each of the regions
3.3 Licensing deals for each of the marketcap group for each of the healthcare sub-sector
3.4 Licensing deals for each of the marketcap group for each of the medicine group
Chapter 4: Analysis of licensing deals of Emerging Markets by medicine groups during last six months
4.1 Licensing deals for each of the medicine group for each of the country
4.2 Licensing deals for each of the medicine group across each of the regions
4.3 Licensing deals for each of the medicine group for each of the healthcare sub-sector
4.4 Licensing deals for each of the medicine group for each of the marketcap group
Chapter 5: Analysis of licensing payment arrangements followed during last six months
5.1 Licensing payment arrangements most followed for each of the country
5.2 Licensing payment arrangements most followed across each of the regions
5.3 Licensing payment arrangements most followed for each of the healthcare sub-sector
5.4 Licensing payment arrangements most followed for each of the marketcap group
5.5 Licensing payment arrangements most followed for each of the medicine group
Chapter 6: Analysis of worldwide licensing vs. domestic licensing during last six months
6.1 Worldwide licensing vs domestic licensing for each of the country
6.2 Worldwide licensing vs domestic licensing across each of the regions
6.3 Worldwide licensing vs domestic licensing for each of the healthcare sub-sector
6.4 Worldwide licensing vs domestic licensing for each of the marketcap group
6.5 Worldwide licensing vs domestic licensing for each of the medicine group
Chapter 7: Analysis of R&D licensing vs commercialization licensing during last six months
7.1 R&D licensing vs commercialization licensing for each of the country
7.2 R&D licensing vs commercialization licensing across each of the regions
7.3 R&D licensing vs commercialization licensing for each of the healthcare sub-sector
7.4 R&D licensing vs commercialization licensing for each of the marketcap group
7.5 R&D licensing vs commercialization licensing for each of the medicine group
Chapter 8: Summary and conclusions

Appendices
Appendix 1 List of companies/institutes covered: By country and company name
Appendix 2 List of companies/institutes covered: By sub-industry, country and company name
Appendix 3 Licensing deals discontinued during last six months
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll